Novo Nordisk A/S 2006 AR2
The report details Novo Nordisk's financial, social, and environmental performance for 2006, highlighting its leadership in diabetes care and expansion in biopharmaceuticals. Key achievements include the US launch of the modern insulin Levemir and the adoption of a UN Resolution on diabetes, which the company actively supported. Environmentally, Novo Nordisk signed a Climate Savers agreement with WWF, committing to a 10% absolute reduction in CO2 emissions by 2014 compared to 2004, and initiated energy screenings at 10 of its 13 production sites. Financially, the company achieved a 15% increase in sales, driven by modern insulins, and improved its gross margin to 75.3%.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2006
Type: AR2
Pages: 124
Novo Nordisk A/S
The report details Novo Nordisk's financial, social, and environmental performance for 2006, highlighting its leadership in diabetes care and expansion in biopharmaceuticals. Key achievements include the US launch of the modern insulin Levemir and the adoption of a UN Resolution on diabetes, which the company actively supported. Environmentally, Novo Nordisk signed a Climate Savers agreement with WWF, committing to a 10% absolute reduction in CO2 emissions by 2014 compared to 2004, and initiated energy screenings at 10 of its 13 production sites. Financially, the company achieved a 15% increase in sales, driven by modern insulins, and improved its gross margin to 75.3%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2006
Reporting Period
Jan 1, 2006 - Dec 31, 2006
Fiscal Year
2006
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees